A genome-wide association study of anorexia nervosa
- PMID: 24514567
- PMCID: PMC4325090
- DOI: 10.1038/mp.2013.187
A genome-wide association study of anorexia nervosa
Abstract
Anorexia nervosa (AN) is a complex and heritable eating disorder characterized by dangerously low body weight. Neither candidate gene studies nor an initial genome-wide association study (GWAS) have yielded significant and replicated results. We performed a GWAS in 2907 cases with AN from 14 countries (15 sites) and 14 860 ancestrally matched controls as part of the Genetic Consortium for AN (GCAN) and the Wellcome Trust Case Control Consortium 3 (WTCCC3). Individual association analyses were conducted in each stratum and meta-analyzed across all 15 discovery data sets. Seventy-six (72 independent) single nucleotide polymorphisms were taken forward for in silico (two data sets) or de novo (13 data sets) replication genotyping in 2677 independent AN cases and 8629 European ancestry controls along with 458 AN cases and 421 controls from Japan. The final global meta-analysis across discovery and replication data sets comprised 5551 AN cases and 21 080 controls. AN subtype analyses (1606 AN restricting; 1445 AN binge-purge) were performed. No findings reached genome-wide significance. Two intronic variants were suggestively associated: rs9839776 (P=3.01 × 10(-7)) in SOX2OT and rs17030795 (P=5.84 × 10(-6)) in PPP3CA. Two additional signals were specific to Europeans: rs1523921 (P=5.76 × 10(-)(6)) between CUL3 and FAM124B and rs1886797 (P=8.05 × 10(-)(6)) near SPATA13. Comparing discovery with replication results, 76% of the effects were in the same direction, an observation highly unlikely to be due to chance (P=4 × 10(-6)), strongly suggesting that true findings exist but our sample, the largest yet reported, was underpowered for their detection. The accrual of large genotyped AN case-control samples should be an immediate priority for the field.
Conflict of interest statement
Cynthia Bulik was a consultant for Shire Pharmaceuticals at the time the manuscript was written.
Federica Tozzi was full time employee of GSK at the time when the study was performed.
David A. Collier was employed by Eli Lilly UK for a portion of the time that this study was performed.
James L. Kennedy has received honoraria from Eli Lilly and Roche.
Robert D. Levitan has received honorarium from Astra-Zeneca.
Figures

References
-
- Klump KL, Bulik CM, Kaye WH, Treasure J, Tyson E. Academy for Eating Disorders position paper: eating disorders are serious mental illnesses. Int J Eat Disord. 2009;42:97–103. - PubMed
-
- Hoek H, van Hoeken D. Review of the prevalence and incidence of eating disorders. Int J Eat Disord. 2003;34:383–396. - PubMed
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition Text Revision. American Psychiatric Press; Washington, DC: 2000.
-
- Lucas AR, Beard CM, O'Fallon WM, Kurland LT. 50-year trends in the incidence of anorexia nervosa in Rochester, Minn.: a population-based study. Am J Psychiatry. 1991;148:917–922. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U24 CA074783/CA/NCI NIH HHS/United States
- R01 MH066122/MH/NIMH NIH HHS/United States
- R01 AA009203/AA/NIAAA NIH HHS/United States
- K01 MH100435/MH/NIMH NIH HHS/United States
- K05 AA000145/AA/NIAAA NIH HHS/United States
- UM1 CA167551/CA/NCI NIH HHS/United States
- MH0662/MH/NIMH NIH HHS/United States
- R37 AA012502/AA/NIAAA NIH HHS/United States
- K02AA018755/AA/NIAAA NIH HHS/United States
- MH066117/MH/NIMH NIH HHS/United States
- F32 NS010045/NS/NINDS NIH HHS/United States
- MH066146/MH/NIMH NIH HHS/United States
- 5R01ES011740/ES/NIEHS NIH HHS/United States
- R01 MH078075/MH/NIMH NIH HHS/United States
- UL1TR000083/TR/NCATS NIH HHS/United States
- MH066288/MH/NIMH NIH HHS/United States
- 088827/WT_/Wellcome Trust/United Kingdom
- R01 CA133996/CA/NCI NIH HHS/United States
- R01 MH066287/MH/NIMH NIH HHS/United States
- P50 CA097007/CA/NCI NIH HHS/United States
- WT088984/WT_/Wellcome Trust/United Kingdom
- 3P50CA093459/CA/NCI NIH HHS/United States
- R01 MH066193/MH/NIMH NIH HHS/United States
- MH066193/MH/NIMH NIH HHS/United States
- 5P50CA097007/CA/NCI NIH HHS/United States
- R01 ES011740/ES/NIEHS NIH HHS/United States
- MH066145/MH/NIMH NIH HHS/United States
- AA-09203/AA/NIAAA NIH HHS/United States
- MR/J006742/1/MRC_/Medical Research Council/United Kingdom
- MR/K500999/1/MRC_/Medical Research Council/United Kingdom
- AA-00145/AA/NIAAA NIH HHS/United States
- R01 MH066296/MH/NIMH NIH HHS/United States
- AA15416/AA/NIAAA NIH HHS/United States
- MH066296/MH/NIMH NIH HHS/United States
- U54 RR0252204-01/RR/NCRR NIH HHS/United States
- R01 MH066147/MH/NIMH NIH HHS/United States
- R01 MH066146/MH/NIMH NIH HHS/United States
- 5R01CA133996/CA/NCI NIH HHS/United States
- K02 AA018755/AA/NIAAA NIH HHS/United States
- 090532/WT_/Wellcome Trust/United Kingdom
- R01 MH066288/MH/NIMH NIH HHS/United States
- T32 MH076694/MH/NIMH NIH HHS/United States
- MH066122/MH/NIMH NIH HHS/United States
- AA-12502/AA/NIAAA NIH HHS/United States
- R01 AA012502/AA/NIAAA NIH HHS/United States
- K12HD001441/HD/NICHD NIH HHS/United States
- R01 AA015416/AA/NIAAA NIH HHS/United States
- R01 MH066117/MH/NIMH NIH HHS/United States
- MH066287/MH/NIMH NIH HHS/United States
- HSRU1/CSO_/Chief Scientist Office/United Kingdom
- R01 MH066145/MH/NIMH NIH HHS/United States
- U01 CA074783/CA/NCI NIH HHS/United States
- WT088827/Z/09/WT_/Wellcome Trust/United Kingdom
- P50 CA093459/CA/NCI NIH HHS/United States
- K12 HD001441/HD/NICHD NIH HHS/United States
- 001/WHO_/World Health Organization/International
- MH066147/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources